Risking public safety: Experts, the medical profession and 'acceptable' drug injury

Health, Risk and Society

Volumn 7, Issue 4, 2005, Pages 379-395

  Abraham, John ^a   Davis, Courtney ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

Anaesthesiology; Drug regulation; Professional closure; Risk assessment; Systems deficit

Indexed keywords

ALTHESIN;

ARTICLE; COMPETENCE; DRUG APPROVAL; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED MEDICINE; FORENSIC MEDICINE; LEGAL LIABILITY; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL EXPERT; MEDICAL PROFESSION; PROFESSIONAL SECRECY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SAFETY; UNITED KINGDOM;

EID: 31144457948     PISSN: 13698575     EISSN: None     Source Type: Journal    
DOI: 10.1080/13698570500390473     Document Type: Article

References (59)

1. Abraham, J. (1994) Bias in science and medical knowledge: The Opren controversy Sociology, 28, pp. 717 - 736.
2. Abraham, J. and Reed, J. (2001) Trading risks for markets: The international harmonization of pharmaceuticals regulation Health, Risk and Society, 3, pp. 113 - 128.
3. Abraham, J. and Reed, J. (2003) Reshaping carcinogenic risk assessment of medicines Social Science and Medicine, 57, pp. 195 - 204.
4. Abraham, J. and Sheppard, J.(1999) The Therapeutic Nightmare: The Battle over the World's most Controversial Sleeping Pill. London: Earthscan.
5. Abraham, J. and Sheppard, J. (1997) Democracy, technocracy and the secret state of medicine: Expert and non-expert perspectives Science, Technology and Human Values, 22, pp. 139 - 167.
6. Alaszewski, A. (2003) Risk, trust and health Health, Risk and Society, 5, pp. 235 - 239.
7. Anon. (1984a) Italian product suspensions Scrip, 862, pp. 1.
8. Anon. (1984b) Glaxo discontinues Althesin Scrip, 882, pp. 17.
9. Austin, T. and Anderson, J. and Richardson, J. (1973) Bronchospasm following Althesin anaesthesia British Medical Journal, 2(5869), pp. 775.
10. Avery, A. and Evans, A. (1973) Reactions to Althesin British Journal of Anaesthesia, 45, pp. 301 - 303.
11. Beamish. (1979) Adverse response to Althesin Anaesthesia, 34, pp. 683 - 684.
12. Beck, U.(1992) Risk Society: Towards a New Modernity. London: Sage.
13. Busfield, J. (2004) Mental health problems, psychotropic drug technologies and risk Health, Risk and Society, 6, pp. 361 - 375.
14. Clarke, R. and Dundee, J. and Garrett, R. and McArdle, G. and Sutton, J. (1975) Adverse reactions to intravenous anaesthetics: A survey of 100 reports British Journal of Anaesthesia, 47, pp. 575 - 585.
15. Committee on Safety of Medicines.(1976) Current Problems. 2 (August)
16. Committee on Safety of Medicines.(1979) Current Problems. 4 (April)
17. Crowther, A. (1973) Bronchospasm following Althesin anaesthesia British Medical Journal, 1, pp. 775.
18. Davis, B. and Pearce, D. (1972) An introduction to Althesin (CT 1341) Postgraduate Medical Journal, June Supplement, pp. 13 - 17.
19. Dimbleby, D.(1977) Eraldin: Across the safety margin. BBC1 Panorama London.. [Television broadcast].
20. Dinmore, P. (1979) Althesin sensitivity testing Anaesthesia, 34, pp. 374 - 375.
21. Dundee, J. and Clarke, R. (1973) Adverse reactions to intravenous anaesthetics British Journal of Anaesthesia, 45, pp. 304.
22. (2004) Expertise in Regulation and Law. Aldershot: Ashgate.
23. Evans, J. and Keogh, J. (1977) Adverse reactions to intravenous anaesthetic induction agents British Medical Journal, 2(6089), pp. 735 - 736.
24. Fisher, M., McD. (1976) Severe histamine mediated reactions to Althesin Anaesthesia and Intensive Care, 4, pp. 33 - 35.
25. Fisher, M., McD. (1979) Sensitivity testing for Althesin Anaesthesia, 34, pp. 906 - 907.
26. Fisher, M., McD and More, D. (1981) The epidemiology and clinical features of anaphylactic reactions in anaesthesia Anaesthesia and Intensive Care, 4, pp. 97.
27. Glaxo.(1974) Althesin data sheet. In.
28. Glaxo.(1974-1976) Althesin data sheets. In.
29. Glaxo.(1977) Althesin data sheet. In.
30. Glaxo.(1982) Althesin data sheet. In.
31. Gordh, T. (1972) The effect of Althesin on the heart in situ in the cat: Discussion Postgraduate Medical Journal, 48, pp. 31 - 37.
32. Hart, S. (1978) Reaction to Althesin British Journal of Anaesthesia, 50, pp. 1169.
33. Healey, T. (1973) Bronchospasm following Althesin induction The Lancet, 2(7835), pp. 975.
34. Hester, J. (1973) Reaction to Althesin British Journal of Anaesthesia, 45, pp. 303.
35. Horton, J. (1973) Adverse reaction to Althesin Anaesthesia, 28, pp. 182 - 183.
36. House of Commons. (1984) Althesin Hansard, 61, pp. 461 - 462. columns
37. House of Commons.(2005) Inquiry into the influence of the pharmaceutical industry, testimony of Sir Alasdair Breckenridge (Chairman of the Board of the UK drug regulatory authority). Hearings before the Health Select Committee, questions 802, 810, 844.
38. Hughes, R. and Inglis, M. and Campbell, D. (1977) Althesin reaction Anaesthesia, 32, pp. 910 - 911.
39. Jago, R. and Restall, J. (1978) Sensitivity testing for Althesin Anaesthesia, 33, pp. 644 - 645.
40. Lam, A. (2000) Tacit knowledge, organizational learning and societal institutions: An integrated framework Organisational Studies, 21, pp. 487 - 513.
41. Mann, R.(1984) Modern Drug Use: An Enquiry on Historical Principles. Lancaster: MTP Press Limited.
42. Mann, R.(1987) The yellow card data: The nature and scale of the adverse drug reactions problem. In Adverse Drug Reactions: The Scale and Nature of the Problem and the Way Forward. (pp. 58).Carnforth Lancashire: Parthenon.
43. McCartney, M. (2005) How were problems with the drug Atomoxetine picked up? Through the invaluable Yellow card scheme Guardian.
44. Mehta, S. (1973) Anaphylactic reaction to Althesin Anaesthesia, 28, pp. 669 - 672.
45. Moldrup, C. and Morgall, J. (2001) Risk society - reconsidered in a drug context Health, Risk and Society, 3, pp. 59 - 74.
46. Moldrup, C. and Morgall, J. and Almarsdottir, A. (2002) Perceived risk of future drugs - a Danish citizen Delphi Health, Risk and Society, 4, pp. 5 - 18.
47. Morgan, M. and Whitwam, J. (1985) Editorial: Althesin Anaesthesia, 40, pp. 121 - 123.
48. Notcutt, W. (1973) Adverse reaction to Althesin Anaesthesia, 28, pp. 673 - 674.
49. Papworth, D. (1983) Adverse reactions to Althesin British Journal of Anaesthesia, 55, pp. 256.
50. Pearce, N.(1996) Adverse reactions, social responses: A tale of two asthma mortality epidemics. In Contested Ground: Public Purpose and Private Interests in the Regulation of Prescription Drugs. (pp. 57-75). New York and Oxford: Oxford University Press.
51. Radford, S. and Lockyer, J. and Simpson, P. (1982) Immunological aspects of adverse reactions to Althesin British Journal of Anaesthesia, 54, pp. 859 - 863.
52. Rothstein, H. (2003) Neglected risk regulation: The institutional attenuation phenomenon Health, Risk and Society, 5, pp. 85 - 103.
53. Sackett, D. and Straus, E. and Richardson, W. and Rosenberg, W. and Haynes, W.(2000) Evidence-based Medicine - How to Practice and Teach EBM. London: Churchill Livingstone.
54. Scott, P. (1979) Sensitivity testing for Althesin Anaesthesia, 34, pp. 86 - 87.
55. Turner, B. (2001) Risks, rights and regulation: An overview Health, Risk and Society, 3, pp. 9 - 18.
56. Walker, S. and Lumley, C.(1987) Reporting and under-reporting. In Adverse Drug Reactions: The Scale and Nature of the Problem and the Way Forward. (pp. 124 - 125).Carnforth Lancashire: Parthenon.
57. Watt, J. (1975) Anaphylactic reactions after use of CT 1341 (Althesin) British Medical Journal, 3(5977), pp. 205 - 206.
58. Weber, J. (1979) Convulsions following Althesin Anaesthesia, 34, pp. 908.
59. Whitwam, J. (1978) Adverse reactions to iv induction agents British Journal of Anaesthesia, 50, pp. 677 - 687.